Viriom develops the new generation of antiviral and anti-infective therapies, preventive and potentially curative medicines that would not only be safe and effective but also affordable. Viriom believes that the fight to eradicate HIV, HBV and other life-threatening infectious diseases can be won by making novel treatments accessible to every patient around the globe. Learn more about our approach to HIV  and our pipeline below.

elpida our solution.jpg

+ Elpida® (elsulfavirine) oral daily and less frequent treatment for HIV-1 Infection

  • Market Authorization

    Elpida® (elsulfavirine) | Treatment for HIV-1 infection

  • Viriom’s lead drug - Elpida® (elsulfavirine 20 mg) is a prescription medicine used with other HIV-1 medicines to treat HIV-1 infection. Elsulfavirine is the pro-drug of the active compound VM1500A (RO4970335), a potent, highly selective NNRTI which obtained market authorization in Russia and is in the process of obtaining new drug authorizations in multiple global markets. Its antiviral profile is superior to all currently marketed NNRTIs.

    In 2009 Viriom licensed a family of patents and drug candidates which gave rise to Elpida® and VM1500A from F. Hoffmann-La Roche. In 2017 Viriom obtained the first market authorization for Elpida® (elsulfavirine) 20 mg-based daily treatment in Russia. Viriom continues to expand registration and commercialization of therapies and preventive medicines with regional and global partners in developing and developed global markets.

    Clinical studies completed to date confirmed excellent tolerability, favorable safety profile and high efficacy of Elpida®. The 48 and 96 week clinical studies confirmed that elsulfavirine 20 mg-based daily regimen in combination with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) was equally efficacious as efavirenz (EFV) 600 mg-based therapy, but significantly better tolerated, safer and more stable to drug-resistant mutations.

    Based on the drug’s favorable pharmacokinetics, Viriom is developing elsulfavirine’s oral less frequent (weekly) dosing regimen for treatment of HIV-1. Viriom prepares for clinical development of an oral weekly dosing of elsulfavirine as Pre- and Post-Exposure Prophylaxis (PrEP and PEP). Elpida® does not cure HIV-1 infection or AIDS.

+ Fixed Dose Combinations Treatment for HIV-1 Infection

  • Bioequivalence

    Elsulfavirine + NRTI and/or INSTI | Treatment for HIV-1 infection

  • A fixed dose combination is two or more drugs contained in a single dosage form, such as a capsule or a tablet. Viriom advances fixed dose combinations of elsulfavirine with other HIV-1 treatments that can be used alone as a complete regimen: including 20 mg elsulfavirine + 200 mg emtricitabine + 300 mg tenofovir in clinic; and experimental dual combinations of elsulfavirine with VM2500 and VM3500 - in pre-clinical development, based on emerging re-examination of triple therapy paradigm.

+ VM1500A Long-Acting Injectable Treatment & Prophylaxis for HIV-1 Infection

  • IND/Phase I

    VM1500A | Treatment for HIV-1 infection

  • Latest studies have shown that some dual-therapy combinations for treatment of HIV-1 seem to achieve the same success as conventional triple regimens, whether in individuals who are naïve to ART or in those who developed resistance to therapy.

    Viriom is developing Long-Acting Injectable nanosuspension of VM1500A - an NNRTI parent drug of elsulfavirine, for once monthly to once in three months administration in combination with other long-acting HIV-1 infection treatments.

    Viriom prepares for clinical development of VM1500A as Pre- and Post-Exposure Prophylaxis (PrEP and PEP).

+ VM2500 Treatment for HIV-1 and HBV Infections

  • Pre-clinical/IND

    VM2500 | Treatment for HIV-1 and HBV infections

  • Viriom is developing an NRTI VM2500 - a novel pro-drug of tenofovir, as a component of combination treatment for HIV-1 and HBV infections.

+ VM3500 Long-Acting Injectable Treatment for HIV-1 Infection

  • Pre-clinical

    VM3500 | Treatment for HIV-1 infection

  • Viriom is developing a long-acting injectable formulation of VM3500 – a novel Integrase Strand Transfer Inhibitor (INSTI) as a component of combination treatment for HIV-1 infection.